



## **Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis**

March 25, 2019

LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced it will hold a webcast and conference call on Tuesday, March 26, 2019 at 8:00 a.m. EDT to provide top-line results from the Phase 3 ALLEVIATE trial of topical ocular reproxalap in patients with allergic conjunctivitis.

The dial-in numbers are 1-877-266-8979 for domestic callers and 1-412-317-5231 for international callers. A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at [www.aldeyra.com](http://www.aldeyra.com). After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.

### ***About Aldeyra Therapeutics***


Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal diseases, post-transplant lymphoproliferative disorder, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

#### Corporate Contact:

David McMullin  
Aldeyra Therapeutics, Inc.  
Tel: 781-761-4904 ext. 218  
[dmcullin@aldeyra.com](mailto:dmcullin@aldeyra.com)

#### Investor Contact:

Chris Brinzey  
Westwicke Partners  
Tel: 339-970-2843  
[Chris.brinzey@westwicke.com](mailto:Chris.brinzey@westwicke.com)

 View original content: <http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-announce-top-line-results-from-the-phase-3-alleviate-trial-in-allergic-conjunctivitis-300817928.html>

SOURCE Aldeyra Therapeutics, Inc.